NIH's RECOMBINANT DNA ADVISORY COMMITTEE SHOULD CONTINUE TO REVIEW GENE THERAPY AS GERMLINE AND SOCIETAL ISSUES ARISE, RAC AD HOC GROUP CONCURS
Executive Summary
Issues related to germline therapy warrant the continued existence of the Recombinant DNA Advisory Committee, ad hoc RAC review committee members agreed at their second meeting March 8 on the National Institutes of Health campus.